Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
2.9
Journals
JCM
Special Issues
Clinical Management for Coronary Artery Disease and Revascularization
jcm-logo
Submit to Special Issue Submit Abstract to Special Issue Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Clinical Management for Coronary Artery Disease and Revascularization

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiovascular Medicine".

Deadline for manuscript submissions: 30 December 2025 | Viewed by 1312

Special Issue Editor

Prof. Dr. Mohammad Reza Movahed

E-Mail Website
Guest Editor
Sarver Heart Center, University of Arizona, Tucson, 245037 AZ, USA
Interests: coronary disease; interventional cardiology; nuclear cardiology; non-invasive cardiology; cardiovascular epidemiology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Coronary artery disease is the leading cause of death in the United States and across the world. The clinical management of this condition is vital in reducing cardiovascular death and morbidity. This Special Issue will focus on updates on the clinical management of coronary artery disease, with a focus on revascularization.

As Guest Editor, I would like to invite you to contribute to our Special Issue, entitled “Clinical Management for Coronary Artery Disease and Revascularization”. We look forward to receiving your contributions.

Prof. Dr. Mohammad Reza Movahed
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • coronary artery disease
  • coronary syndrome
  • stenting
  • revascularization
  • cardiovascular

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

20 pages, 653 KiB  
Article
Prophylactic Intra-Aortic Balloon Pump Implantation Reduces Peri-Interventional Myocardial Injury During High-Risk Percutaneous Coronary Intervention in Patients Presenting with Low Normal Blood Pressure and with Heart Failure
by Sascha d’Almeida, Stefanie Andreß, Sebastian Weinig, Benjamin Mayer, Wolfgang Rottbauer, Sinisa Markovic and Dominik Buckert
J. Clin. Med. 2025, 14(13), 4796; https://doi.org/10.3390/jcm14134796 - 7 Jul 2025
Viewed by 495
Abstract
Background: Intra-aortic balloon pump (IABP) augments coronary perfusion during high-risk percutaneous coronary interventions (PCI). We sought to identify patients who benefited from prophylactic IABP (P-IABP) compared to rescue-IABP (R-IABP). Methods: All consecutive non-cardiogenic shock patients undergoing high-risk PCI with IABP support [...] Read more.
Background: Intra-aortic balloon pump (IABP) augments coronary perfusion during high-risk percutaneous coronary interventions (PCI). We sought to identify patients who benefited from prophylactic IABP (P-IABP) compared to rescue-IABP (R-IABP). Methods: All consecutive non-cardiogenic shock patients undergoing high-risk PCI with IABP support at Ulm University Hospital, Germany, between 2012 and 2020 were grouped based on the timing of IABP insertion in the pre-interventional P-IABP or peri-interventional R-IABP group. We compared the primary endpoint peri-interventional high-sensitivity Troponin T (hsTnT) increase, sought baseline characteristics associated with the endpoint in the R-IABP group, and compared their correlation strengths between the groups. Results: Interventional outcomes of 44 patients with P-IABP implantation were compared with those of 15 patients with R-IABP implantation. P-IABP was associated with a lower peri-interventional hsTnT increase (p = 0.008, r = 0.390). In the R-IABP group, the presence of ST-segment elevation (p = 0.037, r = 0.631), low systolic blood pressure (RRsyst) (p = 0.007, r = 0.893 (inverse correlation)), and elevated NT-proBNP levels (p < 0.001, r = 0.953) were associated with higher hsTnT increases. HsTnT increase was significantly smaller in the P-IABP group in patients with low RRsyst (IZI = 2.6) and high NT-proBNP levels (IZI = 3.36). Patients with RRsyst < 120 mmHg (p = 0.007) and NT-proBNP levels ≥ 900 pg/mL (Cohen’s d = 0.70, respectively 1.17 for ≥5000 pg/mL and 5.01 for ≥10,000 pg/mL) showed lower peri-interventional hsTnT increase when treated with P-IABP compared to R-IABP, while patients with NT-proBNP levels < 900 pg/mL showed a contrary effect (Cohen’s d = −0.90). Cox regression analysis showed that a high peri-interventional hsTnT increase was significantly associated with a shorter survival time (p = 0.046). Conclusions: P-IABP use in high-risk PCI was associated with reduced peri-interventional myocardial injury, as measured by lower hsTnT increase, which was associated with improved survival in patients with low systolic blood pressure and elevated NT-proBNP levels. Thus, these conditions should be considered for indicating P-IABP. Full article
(This article belongs to the Special Issue Clinical Management for Coronary Artery Disease and Revascularization)
►▼ Show Figures

Graphical abstract

10 pages, 325 KiB  
Article
Use of Cell Saver in Elective Coronary Bypass Surgery: What Do We Risk When Saving Blood?
by Adem Reyhancan, Mürsel Büyükadalı, Ertuğrul Koçak, Orkut Güçlü, Serhat Hüseyin and Suat Canbaz
J. Clin. Med. 2025, 14(12), 4230; https://doi.org/10.3390/jcm14124230 - 13 Jun 2025
Viewed by 642
Abstract
Background/Objectives: Allogeneic transfusion is a commonly used method to replace blood and blood elements lost during cardiac surgery, but it also has quite undesirable effects. The use of Cell Saver is now almost routinely recommended. The aim of this study is to investigate [...] Read more.
Background/Objectives: Allogeneic transfusion is a commonly used method to replace blood and blood elements lost during cardiac surgery, but it also has quite undesirable effects. The use of Cell Saver is now almost routinely recommended. The aim of this study is to investigate the clinical and laboratory outcomes of the use of Cell Saver in elective CABG. Methods: Patients who had undergone elective CABG between January 2022 and October 2024 were retrospectively analyzed, and 344 patients were included in the study. Patients were divided into two groups: Cell Saver used (CS, n = 110) and not used (NCS, n = 234). The groups were compared in terms of pre- and postoperative clinical and laboratory outcomes. Results: The mean age of the cases included in the study was 63.65 ± 9.05 years (340 patients, range 36–87). The mean amount of drainage in the first 6 h postoperatively was 298.18 ± 155.81 mL in the NCS group and 388.64 ± 173.62 mL in the CS group (p < 0.001). In the first 24 h, it was 703.22 ± 320.39 mL in the NCS group and 827.73 ± 344.69 mL in the CS group (p = 0.001). Prolonged drainage was more frequent in the CS group (p = 0.004) and the length of hospital stay was longer (p = 0.014). The postoperative albumin level was lower in the CS group (p = 0.003). Conclusions: Although the use of Cell Saver reduces the need for allogeneic transfusions, it leads to increased bleeding in the initial period, prolonged drainage, and thus a longer hospital stay. In elective procedures, blood management should be evaluated and optimized using all methods. Full article
(This article belongs to the Special Issue Clinical Management for Coronary Artery Disease and Revascularization)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop